{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-059189","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.510274+00:00","generated_at":"2026-06-15T04:58:35.865462+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Structure Therapeutics reports Q1 2023 net loss of $18.0M; GSBR-1290 advancing to Phase 2a","bullets":["Net loss of $18.0M for Q1 2023, compared to $13.1M in Q1 2022; non-cash stock-based comp $2.5M.","Cash, cash equivalents and short-term investments totaled $240.9M; expected to fund operations through end of 2025.","R&D expenses $13.1M (up from $8.5M) driven by GLP-1R franchise advancement and stock-based compensation.","GSBR-1290 protocol amendment submitted to FDA to transition to Phase 2a proof-of-concept study in T2DM and obesity.","Topline data from Phase 1b MAD and Phase 2a studies of GSBR-1290 expected in second half 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-059189","json":"https://secwatch.observer/filing/0001104659-23-059189.json","markdown":"https://secwatch.observer/filing/0001104659-23-059189.md","text":"https://secwatch.observer/filing/0001104659-23-059189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923059189/0001104659-23-059189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923059189/tm2315251d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:58:35.865462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"222cd8fd7a14bc22f06f55a05e1f19a32e22ac5f","claim":"Structure Therapeutics Inc. reported the first quarter ended March 31, 2023 results: net income $18.0 million.","evidence_excerpt":"Net loss totaled $18.0 million for the first quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923059189/0001104659-23-059189-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$18.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}